At the news
? BEARISHIMPACT 5/10 424B5 filed Nov 12, 2026 at 16:16 ET
Vir Biotechnology filed a preliminary prospectus supplement for an underwritten public offering of common stock, with size, price, and other terms left as placeholders. The offering follows positive Phase 3 ECLIPSE 1 data for its CHD program and a recent Gilead collaboration. Proceeds will fund pre-commercial activities for the CHD program, TCE oncology platform investments, and general corporate purposes.
- Preliminary prospectus supplement for an underwritten common stock offering filed on November 12, 2026.
- Share count, public offering price, underwriting discounts, and net proceeds are all placeholders (TBD).
- Last reported sale price on November 11, 2026 was $13.13 per share.
- Underwriters have a 30-day option to purchase additional shares.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access